https://www.nationalreview.com/2020/12/the-vaccine-storys-heroes-do-not-fit-the-liberal-narrative/
When it came to solving the crisis, progressive policies took a back seat to the institutions and forces that actually got the job done.
A ssuming that the COVID-19 vaccines work, their development will be the biggest, most high-profile public-health success story since the polio vaccine in the 1950s. A weary world has waited many trying months for this. Yet in the media’s coverage, there are a lot of mixed messages about how this happened — because the story is not one that fits comfortably with liberal narratives. Consider the big, splashy New York Times story by six reporters (Sharon LaFraniere, Katie Thomas, Noah Weiland, David Gelles, Sheryl Gay Stolberg, and Denise Grady) on the Pfizer/BioNTech and Moderna vaccines, and the Stat story by Damian Garde and Jonathan Saltzman on the technology behind them. When you dig into the details, the heroes are largely (1) big American pharmaceutical corporations, (2) the Trump administration, and (3) the U.S. military. The lessons to be drawn support the conservative view of government, business, and their proper roles and relationships.
The tension is obvious early in the Times story, when it announces its intended theme: “In an era of polarized politics, science was able to break down barriers between government, countries and industry to produce one of the few pieces of good news in a year of suffering and division.” This is not supported by the facts. “Science” did not produce a vaccine, in the sense of a Jonas Salk figure having a “eureka!” moment in a laboratory some time in 2020. The Times does not bother introducing us to any of the individual researchers who actually developed the vaccine. Nor does it illustrate the breaking of barriers between countries, except by big business. The facts are more stubborn.
In fact, as the Stat story illustrates, the core concept of making messenger RNA (or mRNA) synthetically and using it to produce vaccines has been kicking around for three decades, and the crucial breakthrough came in 2005. While there were still some daunting scientific hurdles to overcome, the broader problem facing synthetic mRNA was its risky, experimental nature; only a change in the economics and available resources would make it economically viable to invest in scaling up a major trial of an mRNA-based vaccine to see if it would work.